Email this article 
Post a Comment An Overview On Gastroretentive Drug Delivery System
Abstract
Several approaches have been developed to modify drug release after administration via oral route in order to improve pharmacokinetic properties of the drug product in gastro-intestinal system (GIS). Regarding bioavailability of the product, the most important point to be considered for development is the absorption of the drug substance in GI tract. However, absorption of drug substance is affected by various physiological factors such as inability of localization of drug delivery system in desired region of GIS and variable nature of gastric emptying process. This variation causes difficulties on prediction of bioavailability of the active moiety. Indeed, localization of drug delivery systems (DDS) at stomach and proximal part of small intestine provides higher bioavailability, therapeutic activity, less dose application, which leads to higher patient compliance, by the help of the longer contact time of GIS with drug delivery system. In the literature to achieve prolonged gastric retention time, several mechanisms have been developed successfully. Examples of which were floatation, mucoadhesion, sedimentation, expansion, or several delivery systems were developed such as modified shaped system and magnetic systems. In this paper, types of gastroretentive systems, advantages and/or disadvantages of these systems, and recent technologies on this area were reviewed.
References
(1) Rouge N, Buri P, Doelker E. (1996). Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. Int. J. Pharm. 136: 117-139.
(2) Fell JT. (1996). Targeting of drugs and delivery systems to specific sites in the gastrointestinal tract. J. Anat., 189(3): 517-519.
(3) Samaligy SE. (2010). Floating Systems for Oral Controlled Release Drug Delivery. Fachbereich Biologie, Chemie, Pharmazie der Freien Universität, Doctoral Thesis, Berlin. (Adviser: Prof. Dr. Roland Bodmeier).
(4) Kuzu D. (2010). Preparation and characterization of gastroretentive controlled release systems. Master of Science Thesis. http://www.acikarsiv.gazi.edu.tr/index.php?menu=2&secim=10&YayinBIK=4458.
(5) Klausner EA, Lavy E, Friedman M, Hoffman A. (2003b). Expandable gastroretentive dosage forms. J. Cont. Rel., 90(2): 143-162.
(6) Rubinstein A. (1990). Microbially controlled drug delivery to the colon. Biopharm. Drug. Dispos., 11(6): 465-475.
(7) Varis K, Ihamäki T, Härkönen M, Samloff IM, Siurala M. (1979). Gastric Morphology, Function, and Immunology in First-degree Relatives of Probands with Pernicious Anemia and Controls. Scand. J. Gastroenterol., 14(2):129-139.
(8) Holt PR, Rosenberg IH, Russell RM. (1989). Causes and consequences of hypochlorhydria in the elderly. Dig. Dis. Sci. 34(6): 933-937.
(9) Lui CY, Amidon GL, Berardi RR, Fleisher D, Youngberg C, Dressman JB. (1986). Comparison of gastrointestinal pH in dogs and humans: Implications on the use of the beagle dog as a model for oral absorption in humans. J. Pharm. Sci., 75(3): 271-274.
(10) Dressman JB, Berardi RR, Dermentzoglou LC, Russell TL, Schmaltz SP, Barnett JL, Jarvenpaa KM. (1990). Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm. Res., 7(7): 756-761.
(11) Sarna SK. (1985). Cyclic motor activity; migrating motor complex: 1985. Gastroenterology, 89(4): 894-913.
(12) Sarna SK, Otterson MF. (1988). Gastrointestinal motility: some basic concepts. Pharmacology 36(Supp; 1): 7-14.
(13) Deshpande AA, Rhodes CT, Shah NH, Malick AW. (1996). Controlled-Release Drug Delivery Systems for Prolonged Gastric Residence: An Overview. Drug Dev. Ind. Pharm. 22(6): 531-539.
(14) Coupe AJ, Davis SS, Evans DF, Wilding IR. (1991). Correlation of the Gastric Emptying of Nondisintegrating Tablets with Gastrointestinal Motility. Pharm. Res. 8(10): 1281-1285.
(15) Khosla R, Davis SS. (1990). The effect of tablet size on the gastric emptying of non-disintegrating tablets. Int. J. Pharm., 62(2-3): R9-R11.
(16) Timmermans J, Moes AJ. (1994). Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: new data for reconsidering the controversy. J. Pharm. Sci., 83(1): 18-24.
(17) Hocking MP, Brunson ME, Vogel SB. (1988). Effect of various prokinetic agents on post Roux-en-Y gastric emptying. Digestive Diseases and Sciences, 33(10): 1282-1287.
(18) Kaus LC, Fell JT, Sharma H, Taylor DC. (1984). Gastric emptying and intestinal transit of non-disintegrating capsules--the influence of metoclopramide. Int. J. Pharm., 22(1): 99-103.
(19) Bennett CE, Hardy JG, Wilson CG. (1984). The influence of posture on the gastric emptying of antacids. Int. J. Pharm., 21(3): 341-347.
(20) Coupe AJ, Davis SS, Evans DF, Wilding IR. (1992a). The effect of sleep on the gastrointestinal transit of pharmaceutical dosage forms. Int. J. Pharm., 78(1-3): 69-76.
(21) Coupe AJ, Davis SS, Evans DF, Wilding IR. (1992b). Nocturnal scintigraphic imaging to investigate the gastrointestinal transit of dosage forms. J. Control. Rel., 20(2): 155-162.
(22) Hermansson G, Sivertsson R. (1996). Gender-related differences in gastric emptying rate of solid meals. Digest. Dis. Sci., 41(10): 1994-1998
(23) Oth M, Franz M,. Timmermans J,. Moes A. (1992 The bilayer new data for reconsidering thefloating capsule: a stomach-directed drug delivery system for misoprostol. Pharm. Res. 9: 298–302
(24) Agyilirah GA, Green M, DuCret R, Banker GS. (1991) Evaluation of the gastric retention properties of a cross-linked polymer coated tablet versus those of a non-disintegrating tablet. Int. J. Pharm. 5: 241–247
(25) Burke MD, Wilson CG. (2006). Gastroretentive dosage forms: clinical protocol design for gastroretentive dosage forms. Drug. Del. Tech. 6 (8): 26-31.
(26) Coupe AJ, Davis SS, Evans DF, Wilding IR. (1991). Correlation of the Gastric Emptying of Nondisintegrating Tablets with Gastrointestinal Motility. Pharm. Res. 8(10): 1281-1285.
(27) MojaverianP, Vlasses PH, Kellner PE, Rocci JrML. (1988) Effects of gender, posture, and age on gastric residence time of an indigestible solid: pharmaceutical considerations. Pharm. Res. 10: 639–644
(28) Brahma NS, Kwon HK. (2000). Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J. of Cont. Rel., 63: 235–259,
(29) Leung SS, Irons BK, Robinson JR. (1993). Polyanionic hydrogel as a gastric retentive system. J. of Biomat. Sci- Poly. E., 4(5): 483-492.
(30) Gröning R, Heun G. (1984). Oral Dosage Forms with Controlled Gastrointestinal Transit. Drug Dev. Ind. Pharm., 10(4): 527-539.
(31) Srivastava AK, Wadhwa S, Ridhurkar D, Mishra B. (2005). Oral Sustained Delivery of Atenolol from Floating Matrix Tablets-Formulation and In Vitro Evaluation. Drug Dev. Ind. Pharm., 31(3-4): 367-374.
(32) Chen J, Blevins WE, Park H, Park K. (2000). Gastric retention properties of superporous hydrogel composites. J. Control. Rel., 64(1-3): 39-51.
(33) Fix JA, Cargill R, Engle K. (1993). Controlled Gastric Emptying. III. Gastric Residence Time of a Nondisintegrating Geometric Shape in Human Volunteers. Pharm. Res., 10(7): 1087-1089.
(34) Andrews GP, Laverty TP, Jones DS. (2009). Mucoadhesive polymeric platforms for controlled drug delivery. Eur. J. Pharm. Biopharm. 71(3): 505-518.
(35) Swati P, Amita J, Kamala V, Manish N, Chamanlal S. (2011) Gastroretentive delivery of rifampicin: In vitro mucoadhesion and in vivo gamma scintigraphy. Int. J. Pharm. 411(1-2):106-12.
(36) Nappinnai M, Sivaneswari S. (2013). Formulation optimization and characterization ofgastroretentive cefpodoxime proxetil mucoadhesivemicrospheres using 3 2 factorial design. J. Pharm. Res. 7 (4):304-309
(37) Quigley EM. (1996). Gastric and small intestinal motility in health and disease. Gastroenterol. Clin. North. Am. 25(1): 113-145.
(38) Klausner EA, Lavy E, Friedman M, Hoffman A. (2003b). Expandable gastroretentive dosage forms. J. Cont. Rel., 90(2): 143-162.
(39) Fix JA, Cargill R, Engle K. (1993). Controlled Gastric Emptying. III. Gastric Residence Time of a Nondisintegrating Geometric Shape in Human Volunteers. Pharm. Res., 10(7): 1087-1089.
(40) Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC, Falson F. (2006) Gastroretentive dosage forms: Overview and special case of Helicobacter pylori. J. Cont. Rel., 111: 1 – 18.
(41) Clarke GM, Newton JM, Short MB. (1995). Comparative gastrointestinal transit of pellet systems of varying density. Int. J. Pharm., 114(1): 1-11.
(42) Rouge N, Allémann E, Gex-Fabry M, Balant L, Cole ET, Buri P, Doelker E. (1998). Comparative pharmacokinetic study of a floating multiple-unit capsule, a high-density multiple-unit capsule and an immediate-release tablet containing 25 mg atenolol. Pharm. Acta Helv., 73(2): 81-87.
(43) Moe’s AJ. (2003). Gastric retention systems for oral drug delivery, Business Briefing: PharmaTech. 157– 159
(44) Davis DW. (1968). Method of swallowing a pill, United States Patent 3418999
(45) Iannuccelli V, Coppi G, Bernabei MT, Cameroni R. (1998). Air compartment multiple- unit system for prolonged gastric residence. Part I. Formulation study. Int. J. Pharm., 174(1-2): 47-54.
(46) Hilton AK, Deasy PB. (1992). In vitro and in vivo evaluation of an oral sustained-release floating dosage form of amoxycillin trihydrate. Int. J. Pharm., 86(1): 79-88.
(47) Ushimaru KK, Nakamichi K, Saito H. (1987). Pharmaceutical preparations and a method of manufacturing them. US patent 4,702,819.
(48) Sheth PR, Tossounian JL. (1978). Sustained release pharmaceutical capsules. US patent 4,126,672.
(49) Javed A, Shweta A, Alka A, Anil KB, Rakesh KS, Roop KK, Sanjula B.(2007). Formulation and development of hydrodynamically balanced system for metformin: In vitro and in vivo evaluation. Eur. J. Pharm. Biopharm., 67(1):196-201.
(50) Micheals AS. (1974). Drug delivery device with self-actuated mechanism for retaining device in selected area. US patent 3,786,813 A.
(51) Awasthia R, Kulkarni GT. (2013). Development and characterization of amoxicillin loaded floating microballoons for the treatment of Helicobacter pylori induced gastric ulcer. AJPS. 8(3): 174–180.
(52) Srisagul S, Ornlaksana P, Sontaya L, Satit P. (2006). Preparation and in vitro evaluation of a multiple-unit floating drug delivery system based on gas formation technique. Int. J. Pharm. 324: 136–143.
(53) Sandra S, Tamara A, Renata VC, Hendrik M, Karsten M. (2008).New insights on poly(vinyl acetate)-based coated floating tablets: Characterisation of hydration and CO2 generation by benchtop MRI and its relation to drug release and floating strength. Eur. J. Pharm. Biopharm., 69: 708–717.
(54) Rahman Z, Ali M, Khar R.(2006). Design and evaluation of bilayer floating tablets of captopril. Acta Pharm., 56(1):49-57.
(55) Prajapati VD, Jani GK, Khutliwala TA, Zala BS.(2013). Raft forming system-an upcoming approach of gastroretentive drug delivery system. J. Cont. Rel., 168(2):151-65.
(56) Ibrahim HK. (2009). A novel liquid effervescent floating delivery system for sustained drug delivery. Drug Discov. Ther., 3(4):168-75.
(57) Choi BY, Park HJ, Hwang SJ, Park JB. (2002). Preparation of alginate beads for floating drug delivery system: effects of CO2 gas-forming agents. Int. J. Pharm., 239(1-2):81-91.
(58) GroningR., BerntgenM..(1996). Estimation of the gastric residence time of magnetic dosage forms using the Heidelberg capsule, Pharmazie 51 (5): 328– 331
(59) Kumar A, RajeshetV. (2011). Overview of gastroretentive drug delivery system. J. Nat. Conscientia., 2 : 423–436.
(60) Atyabi F, Sharma HL, Mohammad HAH, Fell JT. (1996). Controlled drug release from coated floating ion exchange resin beads. J. Cont. Rel. 42: 25-28
(61) BhowmikD, Chiranjib.B, ChandiraM JayakarB, Kumar KPS. (2009). Floating Drug Delivery System - A Review, Der. Pharm. Let., 1(2):199-218.
DOI: http://dx.doi.org/10.15272%2Fjmpi.v1i4.31
Refbacks
- There are currently no refbacks.
Abstracted & Indexed in :
Comments on this article
-
Coach Factory Outlet awesome temperature among recall
-
Coach Outlet Online neat high temperatures of retention
-
バーバリー 服
-
Questions about generic pills
-
Soma
-
Receiving shale gas: the consequences and the problem
-
are
-
Tainted blood stress
View all commentsby 54 mnklbjoerxqu mnklbjoerxqu mnumlzoeroceLE (2015-02-09)
by 24 mnldumoervjp mnldumoervjp mnuoinoerfrkLE (2015-02-19)
by 33 clenuesweerge clenuesweerge clenuesweergeJE (2015-03-23)
by 53 AdamOWRX AdamOWRX AdamCCAXNF (2016-02-05)
by 69 CarolOHPX CarolOHPX CarolRUCXNE (2016-02-08)
by 53 Vivobite Vivobite Henry (2018-01-04)
by 12 RobertKam RobertKam RobertKamRK (2018-09-19)
by 28 AInjemiinoge AInjemiinoge AInjemiinogex (2018-09-21)